Descripción de la empresa
Immatics N.V. operates as a clinical-stage biopharmaceutical entity dedicated to the research and development of potential T cell redirecting immunotherapies designed for the treatment of cancer within the United States market. The company functions within the Healthcare sector and the Biotechnology industry, positioning itself at the forefront of targeted therapies aimed specifically at treating solid tumors through advanced biological mechanisms. The firm employs a workforce of 589 individuals and holds a total market capitalization of $1.37 billion, while reporting trailing twelve-month revenue of $48.27 million. These valuation metrics, combined with the substantial cash reserves, indicate a mid-to-large cap biotechnology profile that has secured significant funding to advance its pipeline, reflecting a position where market expectations are priced into the stock despite the absence of current profitability. The scale of operations, supported by nearly half a billion dollars in liquid assets, suggests a substantial resource base intended to fund long-term R&D cycles typical for clinical-stage ventures in the biotechnology space.
Salud financiera
The company reported trailing twelve-month revenue of $48.27 million, yet this top-line figure masks a net income loss of $196,447,008 and an EBITDA of $-172,875,008. The significant negative gap between the $48.27 million in revenue and the $196.45 million in net loss reveals a cost structure heavily driven by research and development expenditures that far exceed current sales generation. Free cash flow stands at $-128,190,248, indicating that the company is burning through cash to fuel its development pipeline rather than generating liquidity from operations. This negative cash burn implies a reliance on external capital markets or existing cash reserves to maintain financial flexibility until future commercialization milestones are achieved. The margins present a stark picture of pre-commercial operations, with a gross margin of -280.9%, an operating margin of -196.8%, and a profit margin of 0.0%, all signaling that costs are not covered by revenue at the current stage. On the balance sheet, the company holds $469.34 million in cash against only $15.63 million in debt, supported by a debt-to-equity ratio of 3.23, which suggests a capital structure dominated by equity and cash rather than traditional leverage. The current ratio of 11.72 indicates an extremely high level of short-term liquidity, providing a robust buffer against immediate obligations. Finally, the return on equity is -37.1% and the return on assets is -18.1%, metrics that reflect the dilutive nature of the losses incurred during the development phase rather than operational inefficiency.
Evaluación de valoración
The valuation metrics for Immatics N.V. include a trailing P/E ratio that is effectively unavailable due to negative earnings, while the forward P/E stands at -5.80, implying that the market prices in future earnings that are currently unprofitable. The price-to-book ratio is recorded at 2.45, indicating that the market values the company at a premium of roughly 145% over its net asset book value. The price-to-sales ratio is significantly elevated at 28.48, and the EV/EBITDA multiple is -5.33, suggesting that investors are valuing the firm based on potential future value rather than current cash flows or earnings. The stock has traded between a 52-week high of $12.41 and a 52-week low of $3.45, with the current price sitting at a level that reflects the high risk premium associated with clinical-stage biotechnology assets. With a beta of 1.34, the stock exhibits volatility that is 34% higher than the broader market, highlighting the sensitivity of the share price to market shifts and the inherent risks of the biotechnology sector.
Growth & Income
The company experienced a revenue growth rate of -64.9% year-over-year, while earnings growth is not applicable due to the reported net loss, indicating a contraction in top-line sales rather than an acceleration of profitability. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, all available earnings are theoretically available for reinvestment, though currently consumed by operational deficits. The absence of a dividend yield confirms that the company retains all capital to fund its research initiatives rather than distributing income to shareholders. The overall growth and income profile is characterized by declining revenue and negative earnings, with no current income distribution, reflecting the typical lifecycle stage of a clinical-stage biopharmaceutical company focused on product development.